These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35092540)

  • 1. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
    Chang HY; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A translational platform PBPK model for antibody disposition in the brain.
    Chang HY; Wu S; Meno-Tetang G; Shah DK
    J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis.
    Chang HY; Wu S; Li Y; Zhang W; Burrell M; Webster CI; Shah DK
    MAbs; 2021; 13(1):1874121. PubMed ID: 33499723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced translational PBPK model for transferrin receptor-mediated drug delivery to the brain.
    Sato S; Liu S; Goto A; Yoneyama T; Okita K; Yamamoto S; Hirabayashi H; Iwasaki S; Kusuhara H
    J Control Release; 2023 May; 357():379-393. PubMed ID: 37031741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.
    Wu S; Le Prieult F; Phipps CJ; Mezler M; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):579-592. PubMed ID: 36088452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain.
    Gadkar K; Yadav DB; Zuchero JY; Couch JA; Kanodia J; Kenrick MK; Atwal JK; Dennis MS; Prabhu S; Watts RJ; Joseph SB; Ramanujan S
    Eur J Pharm Biopharm; 2016 Apr; 101():53-61. PubMed ID: 26820920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
    Glassman PM; Chen Y; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice.
    Naoi S; Yamane M; Nemoto T; Kato M; Saito R; Tachibana T
    Drug Metab Pharmacokinet; 2023 Dec; 53():100506. PubMed ID: 38029470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26.
    Thom G; Burrell M; Haqqani AS; Yogi A; Lessard E; Brunette E; Delaney C; Baumann E; Callaghan D; Rodrigo N; Webster CI; Stanimirovic DB
    Mol Pharm; 2018 Apr; 15(4):1420-1431. PubMed ID: 29485883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs.
    Huang HW; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2024 Dec; 51(6):621-638. PubMed ID: 37947924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies.
    Reig-Lopez J; Tang W; Fernandez-Teruel C; Merino-Sanjuan M; Mangas-Sanjuan V; Boulton DW; Sharma P
    Br J Clin Pharmacol; 2023 Sep; 89(9):2691-2702. PubMed ID: 37055941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
    Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
    Khot A; Tibbitts J; Rock D; Shah DK
    AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration.
    Karaoglu Hanzatian D; Schwartz A; Gizatullin F; Erickson J; Deng K; Villanueva R; Stedman C; Harris C; Ghayur T; Goodearl A
    MAbs; 2018 Jul; 10(5):765-777. PubMed ID: 29771629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VHHs as tools for therapeutic protein delivery to the central nervous system.
    Wouters Y; Jaspers T; Rué L; Serneels L; De Strooper B; Dewilde M
    Fluids Barriers CNS; 2022 Oct; 19(1):79. PubMed ID: 36192747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
    Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity.
    Haqqani AS; Thom G; Burrell M; Delaney CE; Brunette E; Baumann E; Sodja C; Jezierski A; Webster C; Stanimirovic DB
    J Neurochem; 2018 Sep; 146(6):735-752. PubMed ID: 29877588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of In vitro transcytosis models to brain targeted biologics.
    Deng K; Lu Y; Finnema SJ; Vangjeli K; Huang J; Huang L; Goodearl A
    PLoS One; 2023; 18(8):e0289970. PubMed ID: 37611031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.